CDKN2C and acute myeloid leukemia: Notably, the KMT2A-MLLT3+ patient samples were separated into two populations: one group of samples showed increased CDKN2C (p18INK4C) expression compared to healthy BM and the other AML subtypes, whereas a distinct subset of patients exhibited low CDKN2C (p18INK4C) levels.